BEAT News & Events

HeartBeam announced a peer-reviewed article in JACC: Advances, a journal of the American College of Cardiology, demonstrating that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The publication is available in the June 2026 issue and online. Key findings include: when the algorithm used a single ECG reading from the HeartBeam device combined with the patient's risk factors and symptoms, it achieved an AUC of 86.5%. AUC or area under the curve is a key measure of performance. When a personal, symptom-free baseline ECG previously recorded on the same HeartBeam device was available for comparison, AUC increased to 92.9%. The algorithm's false-positive rate was significantly lower than the physician panel, indicating fewer patients would be sent unnecessarily to the emergency department.

"In just two months since our last earnings call, we made significant progress executing against the commercialization and growth strategy we've consistently discussed over the last several quarters. We established flagship commercial accounts across New York, Dallas, South Florida and Southern California, advanced our heart attack detection and on-demand 12-lead patch initiatives, and strengthened our balance sheet. HeartBeam's differentiated FDA-cleared synthesized 12-lead ECG platform remains the foundation of our growth, backed by strong IP and clinical evidence," said Robert Eno, Chief Executive Officer, HeartBeam. "Looking ahead, we remain focused on expanding our commercial footprint by driving deep adoption within our flagship accounts and continuing to build out workflow integration and patient onboarding within those practices while continuing to make significant advancements with our patch, heart attack detection and AI initiatives throughout 2026."